Skip to content

Safety profile of COVID-19 vaccines and the comparison to COVID-19 symptomatology

Safety profile of COVID-19 vaccines and the comparison to COVID-19 symptomatology - ImpfSurv

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00024800
Enrollment
7800
Registered
2021-04-26
Start date
2021-04-26
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Z20.8 U07.1

Interventions

Group 1: Longitudinal observational study without intervention with the aim of building a database of symptoms of COVID-19 vaccination or COVID-19 disease or general complaints of subjects not vaccina

Sponsors

Charité - Universitätsmedizin Berlin
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 105 Years

Inclusion criteria

Inclusion criteria: Included in the study are: - Subjects 18 years of age and older   - Subjects who have received COVID-19 vaccination and have not had COVID-19.  - Subjects who have received COVID-19 vaccination and have had COVID-19.  - Subjects who had COVID-19 and were not vaccinated  - Subjects who have not had COVID-19 disease. - Ability to give consent and signed informed consent form.

Exclusion criteria

Exclusion criteria: Subjects without an understanding of the German language will be excluded from the study.  Participants will also be excluded if they are participating or have participated in another (clinical) study that has not been completed 3 months prior to study participation.

Design outcomes

Primary

MeasureTime frame
The primary objective parameter is to assess adverse vaccination reactions in COVID-19 vaccinated individuals compared to the adverse health effects in COVID-19 diseased and non-diseased individuals, respectively. The target parameter will be collected using a newly developed online questionnaire.

Secondary

MeasureTime frame
All other analyses involving predictors influencing vaccination responses or general or health impairments resulting from COVID-19 disease are exploratory.

Countries

Germany

Contacts

Public ContactMaximilian Hinse

Institut für Sozialmedizin, Epidemiologie und Gesundheitsökonomie Charité – Universitätsmedizin Berlin

maximilian.hinse@charite.de+49 (30) – 450 529 133

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026